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Summary.-The study of blocking factors requires a reliable in vitro assay of cell
mediated immunity that parallels the in vivo response. By microcytotoxicity testing,
progressor and immune peripheral blood lymphocytes caused significant target cell
reduction. The cytotoxicity was specific as no cytotoxic effect was detected against
unrelated normal as well as malignant target cell lines. No anti-tumour effect was
noted when progressor peripheral blood lymphocytes were evaluated in the Winn
assay. In marked contrast, immune peripheral blood lymphocytes were capable of
preventing tumour growth in the Winn assay. Furthermore, hamsters repeatedly
immunized with irradiated SV40 tumour cells could resist a live cellchallenge. Thus
immune peripheral blood lymphocytes were chosen as the effector population to
evaluate the abrogation ability of serum in a microcytotoxicity assay.
Serum from hamsters with progressively growing SV40 tumours did not block,
neutralize or potentiate in vitro lymphocytotoxicity. However, serum taken from
hamsters before the appearance of a palpable tumour, potentiated in vitro lympho-
cytoxicity. Serum taken from hamsters hyperimmunized with irradiated SV40
tumour cells, live SV40 virus orfollowing complete excisionofagrowing SV40tumour
armed normal effector cells and potentiated immune effector cells resulting in en-
hanced target cell destruction. Serum alone was not cytotoxic, suggesting a serum
dependent cellular cytotoxicity effect.
Serum from hamsters in which tumours recurred after excision was capable of
abrogating in vitro lymphocytoxicity. However, no antibody activity was detectable
to cell surface antigens by the mixed haemadsorption test in the sera that demon-
strated blocking or potentiating activity. Progressor serum was unable to enhance
the growth of SV40 tumour cells in vivo.
The potentiating and arming activity of serum in this study directly parallels the
cytostatic antibody activity described by Coggin et al. in the hamster SV40 system.
Both cytostatic antibody activity and enhancement of in vitro lymphocytotoxicity
activity correlates with in vivo tumour resistance. These results suggest that
progressive primary tumour growth in this system may correlate with a lack of
serum dependent cellular cytotoxicity rather than blocking factors, while the latter
may be associated with recurrent and/or metastatic disease.
Two CONTRASTING effects of serum on attributed to "blocking antibody". More
in vitro lymphocytotoxicity have been recent evidence has suggested that the
described recently. Serum from animals abrogating factor is an antigen-antibody
or cancer patients with progressively complex or soluble tumour specific antigen
growing tumours can abrogate the in vitro (Alexander, 1974; Baldwin, Price and
destruction of immune lymphocytes Robins, 1973; Currie and Basham, 1972;
(Hellstrom and Hellstrom, 1974). Init- Currie and Alexander, 1974; Sjogren et al.,
ially the abrogating effects of serum was 1971). Abrogation of in vitro destruction
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ofcultivated target cells is termed neutral-
ization if it occurs at the effector cell level
and blocking if it occurs at the target cell
level.
In contrast, non-immune lymphoid
cells can induce target cell lysis in vitro
in the presence of a specific serum
(MacLennan, 1972). The phenomenon
was originally called lymphocyte depen-
dent antibody but is now referred to as
cell dependent antibody (Basham and
Currie, 1974) or antibody dependent
cellular cytotoxicity (DeLandazuri, Kedar
and Fahey, 1974) as the effector cell(s)
has not been exclusively identified as a
lymphocyte. Functionally immune serum
can "arm" non-sensitized effector cells
(Pollack et al., 1972) or "potentiate" the
cytotoxic effect of immune effector cells
(Hellstrom et al., 1973).
The SV40 virus system has been
extensively investigated as a model for
the study oftumour antigens and immune
responses to such antigens (Butel, Tevethia
and Melnick, 1971). While there are data
available on the nature of resistance to
autochthonous andtransplantabletumours
Coggin et al., 1974; Deichman and Klu-
chareva, 1964; Zarling and Tevethia,
1973a, b) in this system, there is little
information on the biological role of serum
factors in the hamster SV40 system.
Girardi (1966) has demonstrated that
serum taken from hamsters after inter-
ruption of SV40 oncogenesis by SV40
transformed human cells could cause
early tumour formation and enhanced
tumour growth in normal hamsters.
While this study was in progress, Coggin
and Anderson (1972) presented data which
suggested that both normal and pro-
gressor serum could block in vitro cell
mediated cytotoxicity. This study was
initiated to see if blocking factors were
present in the serum of hamsters bearing
a transplantable SV40 tumour.
MATERIALS AND METHODS
Hamsters.-Male Syrian golden hamsters
(Mesocrecitus auratus) were obtained from
High Oaks Ranch, Goodwood, Ontario. The
hamsters were maintained on a standard
pellet diet and water ad libitum.
Cell lines.-The H50 cell line (supplied by
Dr S. S. Tevethia) derived originally from a
hamster tumour induced by SV40 virus,
synthesizes intranuclear T antigen, surface
(S) antigen and SV40 transplantation antigen
(Ashkenazi and Melnick, 1963). When trans-
planted in vivo to hamsters it causes a rapidly
growing fatal tumour. In addition, the
SV40 hamstertumourcelllines, F5-1 andLSH
(supplied by Dr J. H. Coggin Jr) and the
SV40 murine tumour cell line SV-3T3 (sup-
plied by Dr G. Poste) were also used. The
BHK21 cell line is a long passaged epithelial
line of normal hamster kidney cells which
transformed spontaneously in vitro and
which causes tumours when transplanted in
vivo (MacPherson and Stoker, 1962). It does
not contain SV40associatedantigens. Mouse
L cells (supplied by Dr L. Prevec) and normal
hamster fibroblasts cultures, prepared in our
laboratory by trypsinizing minced fragments
from newborn hamsters, were also used as
control cell lines.
All cultures were maintained on minimal
essential medium (MEM) (Gibco, Grand
Island, New York) supplemented with 10%
foetal calf serum (FCS) (Rehatuin, Reheis
Chemical Company, Chicago) with added
penicillin and streptomycin (150 iu/ml and
150,ug/ml), Lglutamine (2 mmol/l andsodium
bicarbonate (2.25 g/l).
Immunization
(a) Irradiated H50 cells.-Confluentbottles
of H50 cells were trypsinized, the cells pooled
and centrifuged at 300g for 10 min at room
temperature. The pellet was resuspended in
minimal essential medium with 10% FCS to
a final concentration of 40 x 106/ml. The
cells received 8000 rad of irradiation from a
137CS source during a 50 min time interval.
The number of viable cells was determined
in a haemacytometer using 0.4% trypan blue
diluted with equal parts of normal saline.
Four-to 5-week old hamsters were immunized
intraperitoneally with 4 weekly doses con-
taining 10 million live cells. Two weeks
following the last dose ofirradiated cells each
immunized animal was challenged subcu-
taneously with 105 live unirradiated H50 cells
to confirm andboosttheirimmunity (immune-
transplantable).
(b) Tumour excision.-1 X 106 H50 cells
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were injected intradermally in the inter-
scapular area. Two weeks later hamsters
were lightly anesthetized with ether, an
incision made below the tumour and the
blood vessels to the tumourwvereclamped with
a haemostat. The skin area containing the
tumour mass was cut away, the vessels
severed and a 1 cm piece of Gelfoam (Upjohn,
Don Mills, Ontario) was placed on the
severed vessels as the haemostat was released
in order to control bleeding. The incision
was closedwith7-5mm autoclips (ClayAdams,
New York) and the hamsters were placed
immediately into a 37°C atmosphere until
they revived. The hamsters were observed
for the presence of recurrent growth and
were termed "post-excision" if no regrowth
occurred, and "post-excision regrowth" if
the tumour recurred after a 3-month period.
(c) Live SV40 virus. SV40 virus (sup-
plied by Dr A. J. Girardi) was grown and
titrated on CV1 cells. Virus titrations were
performed in tubes assaying for cytopatho-
genie effect to determine the tissue culture
infectivity dose (TCID5(1).
Adult hamsters were injected with 0-2 ml
of stock SV40 virus (105 TCID 50/ml) sub-
cutaneously once a week for 3 weeks. One
week after the last injection the animals were
challenged with 1 x 105 live H50 cells to
determine their state of immunity (immune
virus).
Isolation ofperipheral blood lymphocytes.
A niixture of Ficoll (Pharmacia, Uppsala,
Sweden)) and Isopaque 440 (Winthrop Lab-
oratories, Aurora, Ontario) containing 24
parts of 9% Ficoll and 10 parts of 34%
Isopaque was prepared according to the
method of Boyum (1968). The density of
the resulting solution was measured with a
hydrometer and adjusted with distilled water
to 1 079. The solution was filtered through
a 0*45 /im millipore membrane and stored at
40C.
Five ml of hamster blood was removed
by cardiac puncture with a 6 ml syringe
containing 1 ml of 0-05 mol/l ethyl-diamine-
tetracetic acid. The blood was diluted to
36 ml with serum-free minimal essential
medium and 9 ml aliquots of diluted blood
were layered on top of 3 ml aliquots of the
prepared gradient mixture. The suspension
was centrifuged at 700 g for 40 min at room
temperature. The upper plasma layer was
removed and saved for future washing steps
followed by the removal of the mononuclear
interface with a Pasteur pipette. The mono-
nuclear cells were washed in a solution con-
taining 15 ml of the plasma layer and 15 ml
of fresh serum-free minimal essential medium
with 200 ethylene glycol tetracetic acid
(EGTA) (Sigma) followed by centrifugation
of 300g for 10 min at 4°C. This washing step
was repeated a second time without incor-
porating 2% EGTA in the serum-free minimal
essential medium. Lymphocytes were
resuspended in 1 ml of serum-free medium
and the concentration ascertained by direct
counting in a haemacytometer. Slides for
differential white blood cell counts were
prepared with the aid of a cytocentrifuge
(Shandon, London).
Tunour cell neutralization assay (Winn,
1961).-H50 target cells were trypsinized
and placed into suspension culture in MEMI
wNith 20% FCS and allowed to incubate for
a minimum of 1 Ii. Normal and immune
peripheral blood lymphocytes were isolated
by the Isopaque-Ficoll method, washed and
adjusted to a concentration of 4 x 107/ml in
MEM. H50 target cells were washed in
MEM and adjusted to a concentration of
4 x 105/ml. Equal volumes of effector and
target cells were incubated at 37°C for 1 h
and 0 05 ml of cell suspension was injected
into the everted hamster cheek pouch. Each
mixture was injected into a minimum of 4
cheek pouches. The cheek pouches were
examined weekly to check for the presence of
tumour.
Cytotoxicity assay (Takasugi and Klein,
1970).-24 h before the test, 75-125 target
cells in 10 yl of 10% MEM were seeded into
each well of the microtest plate (No. 3034,
Falcon Plastics) by a sterile 500 microlitre
Hamilton syringe, fitted with an automatic
dispenser attachment. On the following day,
the medium in the wells was removed by
inverting the plate and applying a sudden
shake. The target cells were then washed
by the addition of serum-free medium. The
number of target cells was determined by
direct count and varying concentrations of
effector cells in 10 ,ul of serum-free medium
were overlaid on the target cells to give the
desired effector to target cell ratio. In each
assay, 6-8 replicate wells were used for each
experimental variable under test. The cells
wvere incubated at 37°C for 1 h; 10 IA of
medium with 20-30% foetal calf serum was
added and the reaction proceeded for 35-40 h
in an atmosphere of 5% CO2 at 37°C. The
669M. H. GOLDROSEN AND P. B. DENT
test was terminated by washing the plate
3 times with medium containing 10% foetal
calf serum at 37°C to preserve viable cells.
The remaining adherent cells were fixed for
30 min in methanol and stained with haemat-
oxylin (20 min) and eosin (10 min). The
stained cells were counted by inserting the
plate under an inverted microscope with a
x 10 objective and a x 12-5 eyepiece fitted
with 100 square grid.
Per cent reduction was defined as follows:
% Reduction-
% Arming:
Target cells remaining
in control wells -
target cells remaining
in test well x 100
Target cells remaining
in control wells
The significance of the inhibitory effect
was calculated by Students 't' test. A P
value of less than 0 05 was considered
significant.
Blocking assay.-Serum to be tested for
blocking was heat inactivated at 56°C for 30
min, centrifuged at 100 g for 5 min in a sero-
fuge II (Clay Adams, New York), diluted
1 : 1 in serum-free minimal essential medium
(MEM) and passed through a 0 45 ,um milli-
pore filter. The blocking effect ofthe diluted
sera on cell mediated destruction of target
cells was tested by the addition of 5 pl ofthe
diluted sera to the microtest wells (3034
Falcon Plastics) at least lh before addition of
the sensitized lymphocytes; 10 jul of effector
cells were added followed by the addition of
5 pl of 40% foetal calf serum (FCS) after a
1 h incubation period.
To test the neutralizing activity of serum,
isolated effector cells were diluted by serial
two-fold dilutions with MEM and an equal
volume of serum diluted 1: 1 with MEM was
added. The serum and effector cells were
allowed to incubate for 1 h at 37°C and then
added to the target cells.
The following formulae were used to
calculate blocking, arming and potentiation:
% Blocking:
% Reduction in the
presence of normal
serum - % Reduction
in the presence of test
serum 10
% Reduction in the x 00
presence of normal
serum
% Potentiation:
Mean number of sur-
viving target cells
with normal lympho-
cytes in the presence
of normal serum -
mean number of sur-
viving target cells
with normal lympho-
cyte in the presence
oftest serum X 100
Mean number of sur-
viving target cells
with normal lympho-
cytes in the presence
of normal serum
% Reduction in the
presence oftest serum
- % Reduction in the
presence of normal
serum x10 % Reduction in theX 100
presence of normal
serum
Mixed Haemadsorption assay.-The mixed
haemadsorption assay (MHA) was performed
as described by Barth, Espmark and Fag-
graeus (1967) with modifications for use in the
hamster system. Hamster anti-sheep red
blood cells (Ha-SRBC (and rabbit anti-ham-
ster gammaglobulin were used in subagglu-
tinating concentrations as previously deter-
mined by checkerboard titration.
To prepare the indicator cells equal vol-
umes of 2% SRBC and the designated dilu-
tion ofHa-SRBC were mixedandincubatedat
room temperature for 1 h. The SRBC were
washed twice with dextrose- gelatin-veronal
buffer (DGV pH 7 0). Equal volumes of
sensitized SRBC and an appropriate dilution
of rabbit anti-hamster gammaglobulin were
mixed and incubated at room temperature for
1 h. The sensitized cells were washed twice
in DGV and resuspended in concentrations
of 0-1% with 10% MEM.
The target cells growing either in 35 mm
Petri dishes (3001, Falcon Plastics) or in
wells of microtest plates (3041, Falcon
Plastics) were washed twice with 10% MEM
before the addition of appropriate dilutions
of test sera. They were incubated for 2 h
at room temperature and then washed twice
with 10% MEM before the addition of the
indicator cells. Following a further 1 h
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incubation the dishes were gently decanted
and refilled with medium while the plates
were washed 4 times. The dishes were
examined under an inverted microscope for
adherent red cells indicative of a positive
test. The microtest plates were inverted and
read on an upright microscope.
In certain experiments, the target cells
were pretreated with 0-125% trypsin/PBS
pH 7-2 or neuraminidase/0-05 sodium acetate
pH 5 5,40 u/ml (Behringwerke, W. Germany)
at 37°C for 1 h. The target cells wAere treated
as previously described.
Enhancement.-To evaluate the effect of
serum on tumour grow,th, serum was collected
from hamsters during early, middle and late
phases of progressive tumour gromwth. The
serum was heat inactivated, clarified by
centrifugation (Serofuge II, Clay Adams,
Newr York) and 0-2 ml of serum (normal,
early, middle, late progressor) was injected
intraperitoneally into a group of hamsters.
Concurrently 1 x 103 or 1 x 104 cells were
injected subcutaneously in the intrascapular
area. Control and experimental hamsters
were monitored weekly for the presence of
tumour.
Comitant tumour immunity.-Hamsters
were inoculated with 1 x 104 H50 cells in
0-2 ml ofminimal essential medium containing
1000 calf serum, subcutaneously in the flank
or intradermally in the interscapular area.
From 7 to 21 days later, groups of 8 hamsters
were challenged with a dose of 103 H50 cells
in the opposite area. Control hamsters
that had not received a primary inoculation
received a tumour cell challenge at the same
time and by the same route as the hamsters
bearing H50 cell transplants. The hamsters
were examined weekly for the presence of
tumour and the first appearance and size of
the tumour at the primary and secondary
sites were recorded.
RESULTS
Since the study of blocking factors
requires a reliable in vitro assay of cell
mediated immunity that parallels the
in vivo response, our first objective was to
correlate in vivo and in vitro cell mediated
anti-tumour immunity. Immune reac-
tivity of hamsters with progressively
growing H50 tumours (3 cm in the greatest
single diameter) as well as hamsters hyper-
immunized to the H50 tumour was
evaluated by a microcytotoxicity assay,
a Winn neutralization test and by direct
challenge.
Cell mediated cytotoxicity ofprogress,or and
immune peripheral blood lymphocytes
The cytotoxic potential of isolated
progressor peripheral blood lymphocytes
was evaluated on H50 tumour cells and
normal hamster fibroblasts. The results
presented in Table I, experiment 1,
indicate that at a ratio of 200: 1, pro-
gressor lymphocytes caused a significant
reduction in the number of surviving
H50 target cells but did not reduce the
number of normal hamster fibroblasts.
Because of the possibility that the
tumour bearers were reacting to antigens
associated with the H50 cell line which
may have been picked up in culture or
other antigens not related to the trans-
formed state, peripheral blood lympho-
cytes were taken from hamsters bearing
tumours which originated in hamsters
injected neonatally with SV40 virus and
passaged exclusively in vivo. Isolated
peripheral blood lymphocytes from ham-
sters bearing 3 cm tumours taken after
the second in vivo passage were tested on
H50 and BHK21 target cells at an effector
to target cell ratio of 100: 1. As shown
in experiment 2 of Table I, significant
cytotoxicity was again observed only on
the H50 cell line.
Peripheral blood lymphocytes were
also taken from hamsters which had been
immunized with irradiated H50 cells and
tested for cytotoxicity in vitro against
H50, BHK21 and normal hamster fibro-
blasts. The results shown in Table II
indicate that significant cytotoxicity was
obtained only against the H50 cells. The
small degree of cytotoxicity observed on
the BHK21 cells was not significant.
W1inn neutralization assay
To obtain further evidence in another
system that the in vitro microcytotoxicity
assay was reflecting the ability of the
effector cells to destroy the target cell in
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TABLE I.-Cell Mediated Cytotoxicity ofProgressor Peripheral BloodLymphocytes on H50
and BHK21 Tumour Cells and Normal Hamster Fibroblasts
Target
Expt cells
1 H50
Normal
fibroblasts
2 H50
BHK21
E:T Effector
ratio source
200: 1 Normal
progressor*
Normal
progressor*
150: 1 Normal
progressort
Normal
progressort
Target cells
remaining
(mean<s.e.)
1285*8±73-9
919*6±28 8
131*8±22-5
157*7±18-6
464-3±22-8
74-0+24- 8
1799-4±139*3
1843*4±174-3
reduction p
28-4 <0 0025
-19-7 NS
84 0 <0 0005
-2-4 NS
* Progressively growing tumour derived from SV40 cells maintained in tissue culture.
t Progressively growing tumour derived from SV40 cells passaged in vivo.
TABLE II.-Cell Mediated Cytotoxicity ofImmune Peripheral Blood Lymphocytes ofH50,
BHK21 Tumour Cells and Normal Hamster Fibroblasts
Target E:T Effector
cells ratio source
H50 400: 1 Normal
Immune
200 : 1 Normal
Immune
Normal 400 : 1 Normal
fibroblasts Immune
200 : 1 Normal
Immune
H50 500 : 1 Normal
Immune
250 : 1 Normal
Immune
BHK21 250 : 1 Normal
Immune
125: 1 Normal
Immune
Target cells
remaining
(mean+s.e.)
510 6±41*1
63*0±13 1
1030-8±21-6
373 5±30 7
676- 6±71- 4
851- 8±36-5
992-5436-0
1014 6±25 0
417-0±14-6
98- 8±12 - 7
562*4±42- 2
398- 6±26- 4
525-5±64-5
459- 1j53-9
895- 8±65- 8
746-4±51 9
reduction
87-7
63-8
-25-9
-2-2
76-3
29-1
12-6
10-6
p
0 0005
0 0005
NS
NS
0 0005
0*0005
NS
NS
TABLE III.-Effect of Immune and Progressor Peripheral Blood Lymphocytes (PBL) On
the Appearance ofTumours in Vivo in the Winn Assay
Expt Cells injected
I Group A (4)*
104 H50
Group B (8)
104 H50+106 Normal PBL
Group C (8)
104 H50+ 106 Immune PBL
2 Group D (8)
104 H50
Group E (6)
104 H50+ 106 Normal PBL
Group F (10)
104 H50+ 106 Progressor PBL
% of cheek pouches with tumours (weeks)
1 2 3 4 5
0 75 100 10 100
50 75 100 100 100
0 0 12*5 12*5 12*5
0 0 50 60 75
0 33 50 60 75
0 20 50 100 100
* Figures in parentheses indicate number of cheek pouches injected; odd percentages are due to the
fact that 3 animals died during the course of the experiment for unexplained reasons.
Expt
1
2
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question, we performed experiments using
the tumour cell neutralization assay
described by Winn (1961). In these
experiments, normal, immune and pro-
gressor peripheral blood lymphocytes,
isolated in the same manner as for the
microcytotoxicity assay, were incubated
with H50 tumour cells at an effector to
target cell ratio of 100: 1. These mix-
tures were then injected into the cheek
pouch of normal hamsters which were
examined weekly for the development of
tumours. The results in Table III
indicate a marked inhibition ofthe growth
of H50 target cells pre-incubated with
immune peripheral blood lymphocytes.
This observation is in contrast to the
failure of inhibition when the tumour cells
were pre-incubated with progressor peri-
pheral blood lymphocytes.
Effect of progressor and post-excision re-
growth serum on lymphocyte cytotoxicity
Based on the general observation that
serum blocking factors can be detected
in vitro about the time a tumour becomes
palpable and thereafter (Hellstrom and
Hellstrom, 1974), we initially screened
progressor serum for blocking activity.
The results in Table IV, experiments 1 and
2, indicate that no abrogation of in vitro
immune lymphocytotoxicity was obtained
with serum from hamsters whose palpable
tumour was less than 3 cm in the largest
diameter (progressor-middle) and from
hamsters whose palpable tumour was
greater than 3 cm in size in the largest
diameter (progressor-late).
As it may not be possible to detect
serum neutralizing activity by theaddition
of the test serum to the target cells, pro-
gressor serum was incubated with the
effector cells and then the effector cells
were added to the target cells. Again, no
abrogation of immune lymphocyte cyto-
toxicity was observed ( Table IV, experi-
ment 3). These results directly contrast
with the observations made with post-
excision regrowth serum. This serum
reduced the cytotoxic potential ofimmune
lymphocytes from 6204% to 2366% in
comparison with normal hamster serum
(Table IV, experiment 4).
Concomitant tumour immunity
Experiments of concomitant tumour
immunity (Bashford et al., 1908) were
performed as other studies reported that
the presence of concomitant tumour
immunity correlated with the absence of
blocking factors (Deekers et al., 1973;
Sjogren and Bansal, 1971). 104 H50 cells
were injected intradermally in the intra-
scapular area of 32 hamsters and on the
following 4 consecutive weeks groups of
TABLE IV. The Effect of Treating Normal and Immune Peripheral Blood Lymphocytes
with Progressor and Post-excision Regrowth Serum on Their Cytotoxicity for Plated H50
Cells
Expt Sertum Donor
I Normal
Progressor
(Middle)
2 Normal
Progressor
(Late)
3 Normal
*Progressor
(Late)
4 Normal
Post-excision
Regrowth
Target cells
normal
lymphocytes
2366-6--474-7
2450-9±61-9
1217- 1±89-9
Remaining± %
s.e. immune % % Poten-
lymphocytes Reduction Blocking Arming tiation
1303-6±97-9 44-9 6-2 - -
1419 9467 1
611 9±73-0
42 - 1
49-7
6-2
0 4 NS
1339-3±72-7 670-5±61-0 49-9
728-5±25-2 269-6±25-2 62-9
681-5±42-4
808- 4±57 - 8
729 0±39 5
240- 1±17-5
304 1±21 4
556- 8±62- 7
64- 7
62-4
- 6-5 2-9 NS
<0 0005
23-6 6-2 <0 0005
* Neutralization experiment.
p
NS
673M. H. GOLDROSEN AND P. B. DENT
8 hamsters were challenged together with
control hamsters with 103 H50 cells
subcutaneously in the groin. The results
shown in Table V indicate that hamsters
bearing a primary H50 tumour (palpable-
2-0 cm size) showed a heightened resist-
ance and not enhanced growth ofa second-
ary challenge compared with normal
controls.
Tumour growth enhancement in vivo
The ability of progressor serum to
enhance tumour growth in vivo was also
evaluated. Hamsters received an intra-
dermal injection of H50 cells, followed by
an intraperitoneal injection of one of the
following sera: early; middle; late pro-
gressor ornormalhamsterserum. Weekly
measurements oftumoursize andincidence
were recorded. The results (Table VI)
do not give any indication of enhanced
tumour growth or a large difference in
tumour incidence when a comparison is
made between the different progressor
sera and normal hamster serum.
Effect of progressor (early), immune and
post-excision serum on lymphocyte cyto-
toxicity
Classically, tumour immunitv has been
demonstrated in models where the animal
was immunized with virus or virus trans-
formed cells, or after complete excision
of a progressively growing tumour. We
wished to determine if immune and post-
excision serum had an effect on tumour
cell growth in vitro. The results shown in
Table VII, experiments 2 and 3 indicate
that immune (virus and transplantable)
and post-excision sera potentiated the
cytotoxic effect of immune effector cells
and were also capable of arming normal
effector cells. This arming and poten-
tiating effect was also present in pro-
gressor serum (early) before the formation
of a palpable tumour (Table VII,
experiment 1).
Mixed haemadsorption test
The mixed haemadsorption antibody
assay was used to determine whether
TABLE V.-Concomitant Tumour Immunity
Time of Size of Incidence ofsecondary tumours in weeks after primary challenge
secondary primary A A
challenge tumour* 1 2 3 4 5 6 7
Tumour bearers 1 Week Palpable - - 0/8 0/8 0/7 0/7 0/4
Controls - - 1/6 2/6 4/6 4/6 4/6
Tumour bearers 2 Weeks 0 5 cm - - - 0/8 0/8 0/7 0/3
Controls - - - 0/6 3/8 4/6 4/6
Tumour bearers 3 Weeks 1 0 cm - - - - - 1/5 1/4
Controls - - - - - 5/6 6/6
Tumour bearers 4 Weeks 2-0 cm - - - - - 0/5 0/5
Controls - - - - - 0/6 2/6
* Measurements refer to greatest single diameter
TABLE VI.-Evaluation ofProgressors Serum's in Vivo Enhancing Ability
Weeks
1 2 3 4
103 Cell dose
Normal hamster serum 2/6 3/6 4/6 3/5
Early progressor serum 0/4 2/4 2/4 2/4
Middle progressor serum 0/4 1/4 3/4 3/3
Late progressor serum 0/4 1/4 2/4 3/4
104 Cell dose
Normal hamster serum 3/6 4/6 4/6 2/3
Early progressor serum 1/4 3/4 3/4 3/4
Middle progressor serum 2/4 4/4 4/4 3/3
Late progressor serum 3/4 4/4 4/4 3/3
674BLOCKING FACTORS IN THE HAMSTER SV40 SYSTEM
TABLE VII. The Effect ofTreating Normal and Immune Peripheral Blood Lymphocytes
with Progressor (Early), Post-excision and Immune Serum on Their Cytotoxicity for Plated
H50 Cells
Expt Seru1m (IO11no
1 Normal
Progressor
(early)
2 Normal
Post-excisioI
3 Normal
Immunle virtus
Immnune
transplantable
Target cells
normal
lymphocytes
808-4+--57-8
551 -6-2:3-9
591- 9+46 -3
500- 1 51-8
976-853- 1
724- 3-42-2
Remainiing X
s.e. immune
lymphocytes
304 1 > 21-4
161 0X20-2
191-3 3 17- 1
28-6-113-3
627-30 44-7
172 -01 11- 9
646-4,A87-9 245 - 5 1:3-4
0l 0 0
10 01 0 Cytotoxicity Blocking Armin1g
62-4 _
0
Potein-
tiation p
31-8 11-8 <0-0005
15-5 39-1 <0-0005
70- 8
67-7
94-2
:35-8
76-2 25-8 112-8 <0-0005
62-0 33-8 73-8 <0-0005
TABLE ATIII. Mixed Haemadsorption Test
Titration
Serum Cell line 1/2--1/64
Progressor eaI-ly HO0,SV3T3
Progressor mi(l(Ile H50,SV3T3
ProgIessor late H50,SV3T3
Post-excision H50,SV3T3
Post-excision (regrowth) H50,SV3T3
Immu1ne transplantable H50,SV3T3
Immune virus H50,SV3T3
Hamster anti-mouse tissute L cells
antibodies to the tumour cell surface
could be detected in the various sera
under study. Each serum was tested on
a minimum of 2-4 SV40 transformed cell
lines. The results shown in Table VIII
indicate that progressor (early, middle,
late) post-excision (clean and regrowth)
and immune (virus, transplantable) sera
constantly gave negative results. The
sera were titrated both in a narrow and
wide range to rule out any prozone effect.
Enzymatic treatment (trypsin, neura-
minidase) of the target cells did not alter
these results, thus ruling out potential
masked antigens as a reason of unreac-
tivity. In contrast, an antiserum raised
in hamsters to normal mouse tissue could
be titrated to a dilution of 10-4 against
normal mouse fibroblasts.
DISCUlSSION
This study was initiated to see if
blocking factors were present in the serum
of hamsters bearing a transplantable
SV40 tumour. The study of blocking
factors requires an in vitro assay of cell
mediated immunity that parallels the
in vivo response. Peripheral blood lymph-
ocytes isolated from hamsters bearing
3 cm, SV40 tumours demonstrated specific
in vitro lymphocytotoxicity but could not
neutralize tumour growth in a Winn test.
Similar observations have been made by
Coggin et al. (1974) with SV40 autochtho-
nous tumours and in other tumour-host
systems (Howell, Dean and Law, 1975).
The study ofHowell et al. (1975) suggested
that the inability to neutralize tumour
growth was due to a lesion in the T cell
system ofthe tumour bearing host. Thus,
progressor peripheral blood lymphocytes
isolated from hamsters bearing 3 cm
tumours would not be an appropriate
effector population to evaluate serum
blocking factors even though these effector
cells demonstrated specific cell mediated
cytolysis in the microcytotoxicity assay.
In contrast, the positive in vitro anti-
tumour effect of immune peripheral blood
lymphocytes demonistrated withthe micro-
1/10-1/10,000
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cytotoxicity assayandWinnneutralization
test correlated with the tumour rejection
observed in the intact animal. Con-
sequently, immune peripheral blood
lymphocytes were chosen as the effector
population to evaluate potential serum
blocking factors in the hamster SV40
system.
This study observed two other effects
of serum besides blocking of in vitro
lymphocytotoxicity. Thus, besidesblock-
ing, each serum had no effect on the
specific cell mediated anti-tumour cyto-
toxic response, or it potentiated the
response. The pattern of serum response
appears to correlate better with resistance
to tumour growth than does the lympho-
cyte reactivity observed in the micro-
cytotoxicity assay.
Contrary to numerous other animal
tumour systems (Hellstrom et al., 1974),
serum blocking factors were not a common
occurrence in association with progressive
tumour growth in our model. In fact,
the only situation where we found serum
blocking factors was in those animals who
experienced a recurrence of a previously
excised tumour. It is important to stress
that serum wastestedforblockingactivity,
both at the target and effector cell level.
In tests of concomitant tumour immunity
enhanced growth in vivo was not seen in
animals with progressively growing tum-
ours, nor did serum taken from these
animals cause enhanced tumour growth
when passively transferred to normal
hosts. Unfortunately, we have not been
able to perform similar studies with sera
demonstrating in vitro blocking activity
(post-excision regrowth).
Serum taken from animals with pro-
gressivelygrowingtumoursneitherblocked
nor potentiated cell mediated cytotoxicity.
The only exception to this was serum
taken from animals shortly after inocu-
lation with a clearly tumourigenic number
of H50 cells, but before the clinical
appearance oftumour. Such sera demon-
strated characteristics similar to sera
taken from animals rendered immune
to tumour transplantation by various
procedures. These immune sera aug-
mented the cytotoxic reactivity oftumour
immunelymphocytesinvitro (potentiation)
(Lamon et al., 1974) and also induced
normal lymphocytes to specifically kill
tumour cells (arming) (Basham and Currie,
1974).
The nature of the serum factors
involved in these phenomena are not clear
from the studies which we have performed
to date. No evidence ofantibodydirected
against the tumour cell surface was
obtained using mixed haemadsorption
tests. The sera alone were not cytotoxic
and attempts to lyse the tumour cells with
such sera in the presence of complement
in classic humoral cytotoxicity assays
were unsuccessful (unpublished obser-
vations).
There is a strong parallel between those
situations in which we have been able to
demonstrate an antibody dependent cel-
lular cytotoxicity effect and those in which
Ambrose, Anderson and Coggin (1971)
demonstrated cytostaticantibodyactivity.
Whether the antibody component of
these two phenomena is identical or
whether two different parameters of anti-
tumour immunity are involved is not
known and requires further study.
Of major importance we feel, is the
fact that there appears to be some rele-
vance of the antibody dependent cellular
cytotoxicity reaction to the actual tumour
host interaction which is not revealed by
classic lymphocytotoxicity tests. Thus,
progressive primary tumour growth may
correlate with a lack of the antibody
component of the antibody dependent
cellular cytotoxicity response rather than
with the presence of a serum blocking
factor. A second area of importance is
the relative rarity of blocking factors in
our model as a feature of progressive
tumour growth. Metastasis in this model
is a rare and very late event, so that it is
conceivable that at least in this system
blocking factors may correlate more with
the presence of recurrent or metastatic
tumour rather than with progressive
tumour growth alone.
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